TABLE 9

Products, inhalers and characteristics of ICS-LABA combination therapies

Prescribing Information: www.accessdata.fda.gov/scripts/cder/daf/(USA), www.fachinfo.de/(EU, Germany), www.medicines.org.uk/emc/(UK).

Active IngredientIndication (Brand)aInhalerDelivered DosePharmacological ProfileClinical Summary
Budesonide + formoterol (fumarate dihydrate)Maintenance treatment of asthma (age ≥ 6 y) (USA/EU)
and COPD (EU)
Symbicort
pMDI
(metered
dose)
DPI
(metered
dose)
160 μg or 80 μg (bud) + 4.5 μg (for)/puff
2 puffs BID
100 or 200 μg (bud) + 6 μg (for) or 400 μg (bud) + 12 μg (for) BID
(≥6–11 y lower dose only)
LABA
and ICS
Prevention of symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone
Beclo-methasone (diproprionate) + formoterol (fumarate dihydrate)Maintenance + reliever treatment of asthma (age ≥ 18 y) and maintenance treatment of COPD (EU)
Fostair Nexthaler
Multidose DPI
(also as pMDI)
81.9 µg (bec-pro) + 5 μg (for-fu-hydr)/actuation
1–2 act. BID, up to 4 ×/day on demand (asthma)
2 actuations BID (COPD)
LABA
and ICS extrafine aerosol
Prevention of symptoms and exacerbations of asthma by symptom-guided treatment in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone
Fluticasone (propionate) + salmeterol (xinafoate)Maintenance treatment of asthma (age ≥ 12 y) and COPD
Advair/Seretide
pMDI DPI45, 115, or 230 μg (flu-pro) + 21μg (sal)/puff 2 puffs BID
93, 233, or 465 μg (flu-
pro) +45 μg (sal) BID, more strength available
LABA
and ICS
Prevention of symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone
Fluticasone (furoate) + vilanterol (trifenatate)Maintenance treatment of asthma (age ≥ 12 y) and COPD
Relvar/Breo Ellipta
DPI92 or 184 µg (flu-fu) +
22 μg (vil)
QD
LABA
and ICS
Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone
Mometasone (fuorate) + indacaterol (acetate)Chronic treatment of asthma (age ≥ 12 y) Atectura BreezhalerDPI62.5, 127.5, or 260 μg
(mom-fu) + 125 μg (ind)
QD
LABA
and ICS
Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone
Mometasone (fuorate) + formoterol (fumarate dihydrate)Maintenance treatment of asthma (age ≥ 5 y) DulerapMDI50, 100, or 200 μg (mom-fu) + 5 μg (for- fu-hydr)/puff
2 puffs BID (5–11 y lowest dose only)
LABA
and ICS
Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone
  • aThe brand names are not meant to be an exhaustive list; they are provided for illustrative purposes, as different products containing the same drugs may have different quantitative compositions, formulations, devices, and overall characteristics.